Literature DB >> 30073421

The hippo pathway provides novel insights into lung cancer and mesothelioma treatment.

Xiao-Lan Liu1, Rui Zuo1, Wen-Bin Ou2.   

Abstract

PURPOSE: Lung cancer and mesothelioma are two types of respiratory disease that have fatal courses and poor prognoses. Although a substantial number of targeted small molecules and antibody drugs have been developed, the 5-year survival rates of these patients remain relatively low. Moreover, most patients inevitably develop clinical resistance to treatment. Therefore, novel therapeutic options and cancer prognostic biomarkers are urgently needed.
METHODS: In this review, we summarized the recent literature from various electronic databases, including PubMed, and highlighted the most advanced findings regarding the hippo pathway in lung cancer and mesothelioma.
CONCLUSION: The hippo signaling transduction pathway has been demonstrated to play crucial roles in lung cancer and mesothelioma pathogenesis, including tumor development and multidrug resistance, and is emerging as a promising therapeutic target, potentially providing new tools for the detection of these tumors at an early stage.

Entities:  

Keywords:  Hippo pathway; Lung cancer; Mesothelioma

Mesh:

Substances:

Year:  2018        PMID: 30073421     DOI: 10.1007/s00432-018-2727-0

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  106 in total

Review 1.  Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer.

Authors:  Takashi Kohno; Takashi Nakaoku; Koji Tsuta; Katsuya Tsuchihara; Shingo Matsumoto; Kiyotaka Yoh; Koichi Goto
Journal:  Transl Lung Cancer Res       Date:  2015-04

2.  RASSF1A Suppresses the Invasion and Metastatic Potential of Human Non-Small Cell Lung Cancer Cells by Inhibiting YAP Activation through the GEF-H1/RhoB Pathway.

Authors:  Fatéméh Dubois; Maureen Keller; Olivier Calvayrac; Fabrice Soncin; Lily Hoa; Alexander Hergovich; Maria-Carla Parrini; Julien Mazières; Mélissa Vaisse-Lesteven; Jacques Camonis; Guénaëlle Levallet; Gérard Zalcman
Journal:  Cancer Res       Date:  2016-01-12       Impact factor: 12.701

3.  YAP1 Regulates OCT4 Activity and SOX2 Expression to Facilitate Self-Renewal and Vascular Mimicry of Stem-Like Cells.

Authors:  Namrata Bora-Singhal; Jonathan Nguyen; Courtney Schaal; Deepak Perumal; Sandeep Singh; Domenico Coppola; Srikumar Chellappan
Journal:  Stem Cells       Date:  2015-06       Impact factor: 6.277

4.  TR1 promotes cell proliferation and inhibits apoptosis through cyclin A and CTGF regulation in non-small cell lung cancer.

Authors:  Li Wang; Zhenhong Chen; Yajuan Wang; De Chang; Longxiang Su; Yinghua Guo; Changting Liu
Journal:  Tumour Biol       Date:  2014-01

Review 5.  Long noncoding RNAs in lung cancer: what we know in 2015.

Authors:  Y J Xu; Y Du; Y Fan
Journal:  Clin Transl Oncol       Date:  2015-12-17       Impact factor: 3.405

6.  A mouse model recapitulating molecular features of human mesothelioma.

Authors:  Deborah A Altomare; Charles A Vaslet; Kristine L Skele; Assunta De Rienzo; Karthik Devarajan; Suresh C Jhanwar; Andrea I McClatchey; Agnes B Kane; Joseph R Testa
Journal:  Cancer Res       Date:  2005-09-15       Impact factor: 12.701

7.  Ajuba LIM proteins are negative regulators of the Hippo signaling pathway.

Authors:  Meghna Das Thakur; Yunfeng Feng; Radhika Jagannathan; Midori J Seppa; James B Skeath; Gregory D Longmore
Journal:  Curr Biol       Date:  2010-03-18       Impact factor: 10.834

Review 8.  The RASSF1A tumor suppressor.

Authors:  Howard Donninger; Michele D Vos; Geoffrey J Clark
Journal:  J Cell Sci       Date:  2007-09-15       Impact factor: 5.285

9.  Aberrant large tumor suppressor 2 (LATS2) gene expression correlates with EGFR mutation and survival in lung adenocarcinomas.

Authors:  Susan Y Luo; Ko-Yung Sit; Alan D L Sihoe; Wai-Sing Suen; Wing-Kuk Au; Ximing Tang; Edmond S K Ma; Wai-Kong Chan; Ignacio I Wistuba; John D Minna; George S W Tsao; David C L Lam
Journal:  Lung Cancer       Date:  2014-06-16       Impact factor: 5.705

Review 10.  The safety and efficacy of osimertinib for the treatment of EGFR T790M mutation positive non-small-cell lung cancer.

Authors:  Xin Gao; Xiuning Le; Daniel B Costa
Journal:  Expert Rev Anticancer Ther       Date:  2016-03-21       Impact factor: 4.512

View more
  4 in total

Review 1.  GPCR-Hippo Signaling in Cancer.

Authors:  Jiaqian Luo; Fa-Xing Yu
Journal:  Cells       Date:  2019-05-08       Impact factor: 6.600

2.  STK3 Suppresses Ovarian Cancer Progression by Activating NF-κB Signaling to Recruit CD8+ T-Cells.

Authors:  Xiangyu Wang; Fengmian Wang; Zhi-Gang Zhang; Xiao-Mei Yang; Rong Zhang
Journal:  J Immunol Res       Date:  2020-09-29       Impact factor: 4.818

3.  Pathological significance and prognostic role of LATS2 in prostate cancer.

Authors:  Tsuyoshi Matsuda; Yasuyoshi Miyata; Yuichiro Nakamura; Asato Otsubo; Yuta Mukae; Junki Harada; Kensuke Mitsunari; Tomohiro Matsuo; Kojiro Ohba; Bungo Furusato; Hideki Sakai
Journal:  Prostate       Date:  2021-09-07       Impact factor: 4.012

Review 4.  Frontiers of ctDNA, targeted therapies, and immunotherapy in non-small-cell lung cancer.

Authors:  Chennianci Zhu; Weihao Zhuang; Limin Chen; Wenyu Yang; Wen-Bin Ou
Journal:  Transl Lung Cancer Res       Date:  2020-02
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.